{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T13:16:27Z","timestamp":1777295787673,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T00:00:00Z","timestamp":1493337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","jfma-online.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.jfma.2017.04.018","type":"journal-article","created":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T23:45:56Z","timestamp":1494373556000},"page":"326-331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors"],"prefix":"10.1016","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7092-0764","authenticated-orcid":false,"given":"Bin-Chi","family":"Liao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Ying","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jih-Hsiang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Chi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Yung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yee-Fan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Chi","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Yuan","family":"Shih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeun-Chung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong-Jen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Chih-Hsin Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pan-Chyr","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2017.04.018_bib1","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jfma.2017.04.018_bib2","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.jfma.2017.04.018_bib3","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2017.04.018_bib4","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.lungcan.2013.11.021","article-title":"Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS)","volume":"83","author":"Yang","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jfma.2017.04.018_bib5","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1200\/JCO.2012.46.1764","article-title":"Symptom control and quality of life in LUX-lung 3: a phase III study of afatinib or cisplatin\/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations","volume":"31","author":"Yang","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2017.04.018_bib6","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2017.04.018_bib7","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non\u2013small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2017.04.018_bib8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jfma.2017.04.018_bib9","doi-asserted-by":"crossref","first-page":"12404","DOI":"10.18632\/oncotarget.7189","article-title":"The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jfma.2017.04.018_bib10","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.jfma.2017.04.018_bib11","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2017.04.018_bib12","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jfma.2017.04.018_bib13","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"J\u00e4nne","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2017.04.018_bib14","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJMoa1413654","article-title":"Rociletinib in EGFR-mutated non\u2013small-cell lung cancer","volume":"372","author":"Sequist","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2017.04.018_bib15","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1634\/theoncologist.2011-0043","article-title":"Outcomes of research biopsies in phase I clinical trials: the MD Anderson Cancer Center experience","volume":"16","author":"El-Osta","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.jfma.2017.04.018_bib16","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/cncr.27916","article-title":"Feasibility and safety of sequential research-related tumor core biopsies in clinical trials","volume":"119","author":"Lee","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.jfma.2017.04.018_bib17","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/nrclinonc.2011.114","article-title":"The ethical use of mandatory research biopsies","volume":"8","author":"Olson","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jfma.2017.04.018_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1200\/JCO.2012.43.1718","article-title":"Use of research biopsies in clinical trials: are risks and benefits adequately discussed?","volume":"31","author":"Overman","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2017.04.018_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2012.44.8589","article-title":"Toward improved understanding of the ethical and clinical issues surrounding mandatory research biopsies","volume":"31","author":"Peppercorn","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jfma.2017.04.018_bib20","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/annonc\/mdt067","article-title":"Attitudes of patients with metastatic breast cancer toward research biopsies","volume":"24","author":"Seah","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jfma.2017.04.018_bib21","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/2159-8274.CD-10-0010","article-title":"The BATTLE Trial: personalizing therapy for lung cancer","volume":"1","author":"Kim","year":"2011","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jfma.2017.04.018_bib22","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/cncr.28966","article-title":"Attitudes toward molecular testing for personalized cancer therapy","volume":"121","author":"Yusuf","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jfma.2017.04.018_bib23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000368161","article-title":"Patients' perceptions of research biopsies in phase I oncology trials","volume":"88","author":"Lemech","year":"2015","journal-title":"Oncology"},{"key":"10.1016\/j.jfma.2017.04.018_bib24","unstructured":"Ministry of Health and Welfare, Executive Yuan, Taiwan. Available at: http:\/\/www.mohw.gov.tw. [Accessed 16 May 2016]."},{"key":"10.1016\/j.jfma.2017.04.018_bib25","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.lungcan.2013.10.005","article-title":"Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy","volume":"82","author":"Tsai","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jfma.2017.04.018_bib26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1183\/09031936.00038907","article-title":"Imprint cytology improves accuracy of computed tomography-guided percutaneous transthoracic needle biopsy","volume":"31","author":"Chang","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jfma.2017.04.018_bib27","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1183\/09031936.04.00030404","article-title":"Value of imprint cytology for ultrasound-guided transthoracic core biopsy","volume":"24","author":"Liao","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jfma.2017.04.018_bib28","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000339412","article-title":"Endobronchial ultrasound-guided transbronchial biopsy of peripheral pulmonary lesions: how many specimens are necessary?","volume":"84","author":"Huang","year":"2012","journal-title":"Respiration"},{"key":"10.1016\/j.jfma.2017.04.018_bib29","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1148\/radiology.217.3.r00dc21685","article-title":"US-guided transthoracic cutting biopsy for peripheral thoracic lesions less than 3 cm in diameter","volume":"217","author":"Liao","year":"2000","journal-title":"Radiology"},{"key":"10.1016\/j.jfma.2017.04.018_bib30","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1148\/radiol.12112077","article-title":"Pleural and peripheral lung lesions: comparison of US- and CT-guided biopsy","volume":"266","author":"Sconfienza","year":"2013","journal-title":"Radiology"},{"key":"10.1016\/j.jfma.2017.04.018_bib31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/JTO.0b013e318233d7dd","article-title":"Percutaneous computed tomography-guided coaxial core biopsy for small pulmonary lesions with ground-glass attenuation","volume":"7","author":"Lu","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jfma.2017.04.018_bib32","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1148\/radiol.12112613","article-title":"Repeat biopsy for mutational analysis of non\u2013small cell lung cancers resistant to previous chemotherapy: adequacy and complications","volume":"265","author":"Yoon","year":"2012","journal-title":"Radiology"},{"key":"10.1016\/j.jfma.2017.04.018_bib33","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/1471-2407-13-130","article-title":"Diagnostic value of endobronchial and endoscopic ultrasound-guided fine needle aspiration for accessible lung cancer lesions after non-diagnostic conventional techniques: a prospective study","volume":"13","author":"Bugalho","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jfma.2017.04.018_bib34","doi-asserted-by":"crossref","unstructured":"Lin M-W, Tseng Y-H, Lee Y-F, Hsieh M-S, Ko W-C, Chen J-Y. et\u00a0al. Computed tomography-guided patent blue vital dye localization of pulmonary nodules in uniportal thoracoscopy. J Thorac Cardiovasc Surg. In press. doi: 10.1016\/j.jtcvs.2016.04.052.","DOI":"10.1016\/j.jtcvs.2016.04.052"},{"key":"10.1016\/j.jfma.2017.04.018_bib35","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.lungcan.2013.08.023","article-title":"Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors","volume":"82","author":"Sun","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jfma.2017.04.018_bib36","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1158\/0008-5472.CAN-15-2581","article-title":"EGF816 exerts anticancer effects in non\u2013small cell lung cancer by irreversibly and selectively targeting primary and acquired activating mutations in the EGF receptor","volume":"76","author":"Jia","year":"2016","journal-title":"Cancer Res"},{"issue":"15_suppl","key":"10.1016\/j.jfma.2017.04.018_bib37","doi-asserted-by":"crossref","first-page":"8083","DOI":"10.1200\/jco.2015.33.15_suppl.8083","article-title":"Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC [abstract]","volume":"33","author":"Yu","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2017.04.018_bib38","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1158\/1078-0432.CCR-15-1031","article-title":"Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses","volume":"22","author":"Sundaresan","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jfma.2017.04.018_bib39","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.acra.2008.02.018","article-title":"Computed tomography\u2013navigated transthoracic core biopsy of pulmonary lesions: which factors affect diagnostic yield and complication rates?","volume":"15","author":"Heyer","year":"2008","journal-title":"Acad Radiol"},{"key":"10.1016\/j.jfma.2017.04.018_bib40","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1007\/s11547-007-0212-y","article-title":"Accuracy of CT-guided transthoracic needle biopsy of lung lesions: factors affecting diagnostic yield","volume":"112","author":"Priola","year":"2007","journal-title":"Radiol Med"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664617303534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664617303534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T05:36:05Z","timestamp":1602048965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664617303534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0929664617303534"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2017.04.018","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2017.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}